title: CpG-oligodeoxynucleotides suppress the proliferation of A549 lung adenocarcinoma cells via toll-like receptor 9 signaling and upregulation of Runt-related transcription factor 3 expression.
abstract: The aim of the present study was to investigate the effect of CpG-oligodeoxynucelotides (CpG-ODN) on the proliferation of the A549 human lung adenocarcinoma cell line and the expression of Runt-related transcription factor 3 (Runx3) and investigate the association between the toll-like receptor 9 (TLR9) signaling pathway and Runx3 expression during A549 cell proliferation. Different concentrations of CpG-ODN were used in this study to stimulate A549 cells and the expression of Runx3 at the mRNA or protein level was detected by reverse transcription-polymerase chain reaction or western blot analysis. Moreover, Runx3 siRNA was synthesized and transiently transfected into the A549 cells and the MTT assay was used to detect the effects of CpG-ODN on transfected cell growth. Our data demonstrated that CpG-ODN significantly inhibited the proliferation of A549 cells. The expression of Runx3 in the mRNA and protein level was increased in A549 cells stimulated by CpG-ODN. The CpG-ODN-stimulated cell proliferation was significantly inhibited in Runx3 siRNA-transfected A549 cells. In conclusion, CpG-ODN may bind to TLR9, inhibit the proliferation of A549 cells and upregulate the expression of Runx3.
authors.affiliation: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.
authors.forename: Prince Amoah
authors.initials: PA
authors.lastname: Barnie
authors.affiliation: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.
authors.forename: Pan
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China.
authors.forename: Ping
authors.initials: P
authors.lastname: Lu
authors.affiliation: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.
authors.forename: Zhaoliang
authors.initials: Z
authors.lastname: Su
authors.affiliation: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.
authors.forename: Shengjun
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.
authors.forename: Huaxi
authors.initials: H
authors.lastname: Xu
keywords: A549 cancer cells; CpG-oligodeoxynucleotides; Runt-related transcription factor 3; proliferation; toll-like receptor 9
references.citation: Oncogene. 2008 Jan 7;27(2):225-33
references.pmid: 18176604
references.citation: Cancer Sci. 2003 Mar;94(3):230-4
references.pmid: 12824914
references.citation: PLoS One. 2013 Sep 09;8(9):e73894
references.pmid: 24040108
references.citation: Oncoimmunology. 2013 Aug 1;2(8):e25123
references.pmid: 24083076
references.citation: J Clin Pathol. 2004 Mar;57(3):294-9
references.pmid: 14990603
references.citation: Mol Cell Biol. 2006 Jun;26(12):4474-88
references.pmid: 16738314
references.citation: EMBO J. 2004 Feb 25;23(4):969-79
references.pmid: 14765120
references.citation: Clin Cancer Res. 2013 Feb 1;19(3):680-90
references.pmid: 23230322
references.citation: Cancer Biol Ther. 2007 Nov;6(11):1704-9
references.pmid: 17986857
references.citation: Nat Immunol. 2007 Feb;8(2):145-53
references.pmid: 17195845
references.citation: Int J Med Microbiol. 2005 Jun;295(3):179-85
references.pmid: 16044857
references.citation: Seikagaku. 2012 Apr;84(4):278-82
references.pmid: 22712235
references.citation: Int J Immunogenet. 2010 Apr;37(2):111-5
references.pmid: 20193034
references.citation: Mol Med Rep. 2013 May;7(5):1425-30
references.pmid: 23504038
references.citation: Biochem Biophys Res Commun. 2004 Jan 30;314(1):223-8
references.pmid: 14715269
references.citation: Int J Oncol. 2013 Nov;43(5):1511-6
references.pmid: 24042352
references.citation: Clin Dev Immunol. 2012;2012:949821
references.pmid: 23243425
references.citation: Am J Pathol. 2003 Aug;163(2):387-91
references.pmid: 12875960
references.citation: J Immunol. 2005 Dec 15;175(12):8242-52
references.pmid: 16339564
references.citation: Nat Immunol. 2003 Jul;4(7):687-93
references.pmid: 12766768